[12] Patent
[11] Patent No.:GC0009341  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/141374
Date of the Decision to Grant the Patent:11/Dec/2018

[21] Application No.:GC 2012-22521

[22] Filing Date:13/10/2012

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
14/10/2011
61/547,292

[72] Inventors:1- ORWAT, Michael J.،2- PINTO, Donald J.P.،3- SMITH II, Leon M.،4- SRIVASTAVA, Shefali

[73] Owner: BRISTOL-MYERS SQUIBB COMPANY, Route 206 and Province Line Rd. NJ 08543, Princeton, USA

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 31/4725, 31/496, 31/5377, 31/541, 31/55;, 31/551; C07D 217/26, 401/04, 401/10, 401/14, 413/14, 471/10, 487/04, 487/08, 487/10, 491/10, 491/107, 491/113 (2006.01)

[56] Cited Documents:

-WO 2005014533 A2 CTRANSTECH PHARMA INC [US]; MJALLI ADMAN M M [US]; ANDREWS ROBERT C [US) 17 February 2005
-WO 03041641 A2 (SQUIBB BRISTOL MYERS CO [US]; HERMSMEIER MARK ALDEN [US]; RAWLINS DAVI) 22 May 2003
 
Examiner: PH. Nada A. AlShamrani

[54] SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS
[57] Abstract: The present invention provides compounds of Formula (I): (I)or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
No. of claims: 17     No. of figures: 11


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.